Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 13/20 | 0.63 |
| ▸ | NPC1 | O15118 | 8/20 | 0.63 |
| ▸ | RAB9A | P51151 | 7/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.63 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132534 | 1.00 | GAA (0.63) | GAANPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL29663046 | 0.84 | RAB9A (0.77) | GAANPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL22873999 | 0.84 | RAB9A (0.77) | GAANPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL21626743 | 0.81 | KCNH2 (0.73) | GAANPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL1132258 | 0.81 | GAA (0.55) | GAANPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL1132257 | 0.81 | GAA (0.55) | GAANPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL1164775 | 0.78 | RAB9A (0.72) | GAANPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL1164776 | 0.78 | RAB9A (0.72) | GAANPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL20625512 | 0.76 | KCNH2 (0.62) | GAANPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL8264584 | 0.76 | KMT2A (0.52) | GAANPC1RAB9ASMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512066-B2 | Enhancers of protein degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2016-12-06 | — | — | US | claimed |
| US-20120282629-A1 | Enhancers of Protein Degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2012-11-08 | — | — | US | claimed |
| EP-2488485-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-08-22 | — | — | EP | claimed |
| WO-2011020883-A9 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-07-12 | — | — | WO | claimed |
| WO-2011020883-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2011-02-24 | — | — | WO | claimed |
| EP-2287149-A1 | Enhancers of protein degradation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2011-02-23 | — | — | EP | claimed |
| US-9512066-B2 | Enhancers of protein degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20120282629-A1 | Enhancers of Protein Degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2012-11-08 | — | — | US | disclosed |
| EP-2488485-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011020883-A9 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-07-12 | — | — | WO | disclosed |
| WO-2011020883-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2011-02-24 | — | — | WO | disclosed |
| EP-2287149-A1 | Enhancers of protein degradation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2011-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282629-A1 | Enhancers of Protein Degradation | HTT, HYPK, TFEB | GAA 115/4885NPC1 898/4885RAB9A 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.